Get the Daily Brief
Latest Biotech News
Regulatory and FDA leadership shifts
The FDA moved to change leadership of its biologics oversight structure, naming Katherine Szarama as acting director of the Center for Biologics Evaluation and Research (CBER), which regulates...
Oncology FDA advisory outcomes and label-risk dynamics
Two separate FDA advisory panel threads highlighted how evidence standards for oncology use cases are tightening. An ODAC discussion of AstraZeneca’s oral SERD camizestrant produced a near-split...
Biotech funding via IPOs
Two IPO debuts underscored strong investor appetite for late-stage-ready and category-defining specialties. Seaport Therapeutics and Hemab Therapeutics entered public markets through a combined...
M&A and rare disease platform expansion
Chiesi Group agreed to acquire KalVista Pharmaceuticals in a $1.9 billion deal, extending its rare disease footprint with Ekterly (sebetralstat), a plasma kallikrein inhibitor for hereditary...
Cell therapy and immune engineering—clinical signals
Stem cell memory-enriched CAR T data moved into the spotlight as a first-in-human program reported complete remissions at low doses without chemotherapy preconditioning. The approach uses stem...
Gene therapy and vector development—regulatory and preclinical progress
UniQure advanced its regulatory recovery path for Huntington’s disease, planning a UK marketing application for AMT-130 after a positive meeting with UK regulators. The decision is backed by...
Clinical trial failure or regulatory risk in oncology
Bristol Myers Squibb’s Krazati (fruquintinib) moved into approval-risk territory after failing a confirmatory Phase 3 study in second-line colorectal cancer. The company spokesperson confirmed to...
New clinical evidence for GLP-1 outside classic metabolic targets
Semaglutide moved beyond standard obesity and diabetes endpoints as a small clinical trial reported lower heavy drinking days among individuals with alcohol use disorder and obesity. Investigators...
Microbiome and immunology drug discovery signals
Microbiome-derived therapy advanced as researchers reported Bifidobacterium-derived nanoparticles that combat alcoholic liver disease via mechanisms linked to biophysical and inflammatory...
Cell and gene engineering platforms—scalable genome editing and synthesis
Biohub moved to scale “virtual cell” tooling with a major $500 million commitment to build AI-based predictive cell models, aiming to generate multimodal datasets and open access resources. The...
Regulatory action / rare disease drug integrity
The FDA moved to withdraw Tavneos (avacopan) from the US market after investigators found serious data-integrity issues in the pivotal trial that supported approval. The drug, developed by...
Oncology FDA advisory committee stance on ctDNA-guided switching
FDA oncology advisors again pushed back on AstraZeneca’s ctDNA-driven switching strategy for camizestrant. Two separate ODAC-focused writeups (one noting a related “new paradigm” framing and one...
FDA real-time trial data initiative for oncology
The FDA is preparing to use real-time clinical trial data review in oncology, starting with studies from Amgen and AstraZeneca. The agency’s approach aims to reduce the lag between trial conduct...
Biotech IPO funding and market access
Avalyn Pharma raised $300 million in an upsized IPO to fund late-stage development of reformulated inhaled respiratory therapies. The company priced its offering at $18 per share, with gross...
Acquisition / rare disease commercial expansion
Chiesi agreed to buy KalVista Pharmaceuticals for about $1.9 billion, adding Ekterly (sebetralstat) to its rare disease portfolio. The acquisition is designed to bolster Chiesi’s presence in...
Gene therapy regulatory pursuit after US setback
UniQure said it plans to seek UK approval of its Huntington’s gene therapy AMT-130 after a positive meeting with UK regulators. The company pointed to three-year analyses from ongoing studies in...
Biotech financing / early clinical pipeline capital raise
Tacalyx secured €11 million in a first closing of a seed extension round to advance TCX-201, an antibody-drug conjugate targeting an undisclosed tumor-associated carbohydrate antigen. The funding...
Platform/diagnostic partnership in oncology companion testing
Guardant Health and Nuvalent entered a multi-year strategic collaboration to develop and potentially commercialize oncology companion diagnostics using Guardant’s tissue and liquid biopsy assets....
Clinical trial signal / neurodevelopmental and metabolic link
Researchers reported that once-weekly semaglutide can reduce heavy drinking days in people with alcohol use disorder and obesity, based on results published in The Lancet from a small trial. The...
Research breakthrough / immune mechanism for cancer killing
Weill Cornell Medicine researchers reported in Cancer Cell that activated T cells release extracellular vesicles carrying DNA fragments that can boost anti-tumor immune activity. The study ties a...